A bio-nanocapsule containing envelope protein domain III of Japanese encephalitis virus protects mice against lethal Japanese encephalitis virus infection.

Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 7703966 Publication Model: Print Cited Medium: Internet ISSN: 1348-0421 (Electronic) Linking ISSN: 03855600 NLM ISO Abbreviation: Microbiol Immunol Subsets: MEDLINE

Publication: <2008- > : Richmond : Wiley-Blackwell
Original Publication: 1977-<2007> : Tokyo : Center for Academic Publications Japan.

Drug Carriers/*administration & dosage ; Encephalitis Virus, Japanese/*immunology ; Japanese Encephalitis Vaccines/*immunology ; Nanocapsules/*administration & dosage ; Viral Envelope Proteins/*immunology; Animals ; Antibodies, Viral/blood ; Encephalitis Virus, Japanese/genetics ; Escherichia coli/genetics ; Female ; Immunoglobulin G/blood ; Japanese Encephalitis Vaccines/administration & dosage ; Mice ; Mice, Inbred BALB C ; Protein Binding ; Recombinant Proteins/genetics ; Recombinant Proteins/immunology ; Staphylococcal Protein A/genetics ; Staphylococcal Protein A/metabolism ; Survival Analysis ; Vaccination/methods ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology ; Viral Envelope Proteins/genetics

An engineered bio-nanocapsule (BNC) comprising modified hepatitis B surface antigen L protein was used as a physical scaffold for envelope protein domain III (D3) of Japanese encephalitis virus (JEV). At the N terminus, the BNC contained a two-tandem repeat of the Z domain (ZZ) derived from Staphylococcus aureus protein A (ZZ-BNC). The Lys-rich ZZ moiety exposed on the surface of ZZ-BNC was used for chemical conjugation with the JEV D3 antigen, which had been expressed and purified from Escherichia coli. Immunization of mice with D3 loaded on the surface of ZZ-BNC (ZZ-BNC:D3) augmented serum IgG response against JEV and increased protection against lethal JEV infection. The present study suggests that innocuous recombinant antigens, when loaded on the surface of ZZ-BNC, can be transformed to immunogenic antigens.
(© 2013 The Societies and Wiley Publishing Asia Pty Ltd.)

0 (Antibodies, Viral)
0 (Drug Carriers)
0 (Immunoglobulin G)
0 (Japanese Encephalitis Vaccines)
0 (Nanocapsules)
0 (Recombinant Proteins)
0 (Staphylococcal Protein A)
0 (Vaccines, Synthetic)
0 (Viral Envelope Proteins)

Date Created: 20130619 Date Completed: 20140102 Latest Revision: 20130618

20250114

10.1111/1348-0421.12055

23773026